Using Health Technology Assessment to Inform Insurance Reimbursement of High Technology Medicines in China: an Example of Cancer Immunotherapy

Overview

Journal BMJ

Specialty General Medicine

Date 2023 Jun 15

PMID 37321628

Authors

Yingyao Chen

Hengjin Dong

Yan Wei

Yi Yang

Jian Ming

Hao Yu

Affiliations

Soon will be listed here.

Citing Articles

Systematic review of the impact of the National Medication Price Negotiated Policy on the accessibility of drugs in China, 2016-2024.

Peng N, Du C, Gong Y, Long X, Wang C, Liu P BMJ Open. 2024; 14(12):e087190.

PMID: 39725414 PMC: 11683965. DOI: 10.1136/bmjopen-2024-087190.

First-Line Camrelizumab Plus Rivoceranib in Advanced Hepatocellular Carcinoma: A China-Based Cost-Effectiveness Analysis.

Xiang G, Huang Y, Zhang N, Du X, Wu Y, Gan L Clin Med Insights Oncol. 2024; 18:11795549241299393.

PMID: 39582517 PMC: 11585044. DOI: 10.1177/11795549241299393.

Assessment of national reimbursement anticancer medications availability in China: based on a medical institution perspective.

Meng W, Yang S, Wang Z, Xie J, Jiang R BMC Public Health. 2024; 24(1):2268.

PMID: 39169407 PMC: 11337886. DOI: 10.1186/s12889-024-19786-y.

Impact of competition on reimbursement decisions for cancer drugs in China: an observational study.

Guan H, Shi Y, Song J, Cao M, Sun A, Liu S Lancet Reg Health West Pac. 2024; 50:101157.

PMID: 39156118 PMC: 11326914. DOI: 10.1016/j.lanwpc.2024.101157.

Developing mapping algorithms to predict EQ-5D health utility values from Bath Ankylosing Spondylitis Disease Activity Index and Bath Ankylosing Spondylitis Functional Index among patients with Ankylosing Spondylitis.

Yu L, Yang H, Lu L, Fang Y, Zhang X, Li S Health Qual Life Outcomes. 2024; 22(1):61.

PMID: 39113080 PMC: 11304938. DOI: 10.1186/s12955-024-02276-5.

References

Kolasa K, Kalo Z, Zah V, Dolezal T . Role of health technology assessment in the process of implementation of the EU Transparency Directive: relevant experience from Central Eastern European countries. Expert Rev Pharmacoecon Outcomes Res. 2012; 12(3):283-7. DOI: 10.1586/erp.12.12. View

Chalmers I, Bracken M, Djulbegovic B, Garattini S, Grant J, Gulmezoglu A . How to increase value and reduce waste when research priorities are set. Lancet. 2014; 383(9912):156-65. DOI: 10.1016/S0140-6736(13)62229-1. View

Blankart K, Stargardt T . The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany. Health Econ. 2020; 29 Suppl 1:63-82. DOI: 10.1002/hec.4108. View

Ngorsuraches S, Meng W, Kim B, Kulsomboon V . Drug reimbursement decision-making in Thailand, China, and South Korea. Value Health. 2012; 15(1 Suppl):S120-5. DOI: 10.1016/j.jval.2011.11.002. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View

Facey K, Boivin A, Gracia J, Hansen H, Lo Scalzo A, Mossman J . Patients' perspectives in health technology assessment: a route to robust evidence and fair deliberation. Int J Technol Assess Health Care. 2010; 26(3):334-40. DOI: 10.1017/S0266462310000395. View

Prasad V, Mailankody S . The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable. Mayo Clin Proc. 2016; 91(6):707-12. DOI: 10.1016/j.mayocp.2016.04.028. View

Beaver J, Pazdur R . The Wild West of Checkpoint Inhibitor Development. N Engl J Med. 2021; 386(14):1297-1301. DOI: 10.1056/NEJMp2116863. View

Cai Y, Xue M, Chen W, Hu M, Miao Z, Lan L . Expenditure of hospital care on cancer in China, from 2011 to 2015. Chin J Cancer Res. 2017; 29(3):253-262. PMC: 5497212. DOI: 10.21147/j.issn.1000-9604.2017.03.11. View

10.

Yang Z, Zhu Y, Xiang G, Hua T, Ni J, Zhao J . First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China. Expert Rev Pharmacoecon Outcomes Res. 2021; 21(5):1061-1067. DOI: 10.1080/14737167.2021.1899813. View

11.

Hwang T, Kesselheim A, Rome B . New Reforms to Prescription Drug Pricing in the US: Opportunities and Challenges. JAMA. 2022; 328(11):1041-1042. DOI: 10.1001/jama.2022.15268. View

12.

Fleurette F, Banta D . Health technology assessment in France. Int J Technol Assess Health Care. 2000; 16(2):400-11. DOI: 10.1017/s0266462300101060. View

13.

Kim H, Liew D, Goodall S . Cost-effectiveness and financial risks associated with immune checkpoint inhibitor therapy. Br J Clin Pharmacol. 2020; 86(9):1703-1710. PMC: 7444763. DOI: 10.1111/bcp.14337. View

14.

June C, OConnor R, Kawalekar O, Ghassemi S, Milone M . CAR T cell immunotherapy for human cancer. Science. 2018; 359(6382):1361-1365. DOI: 10.1126/science.aar6711. View

15.

Liao W, Huang J, Hutton D, Li Q . Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China. J Med Econ. 2019; 22(4):344-349. DOI: 10.1080/13696998.2019.1570221. View

16.

Rodwin M . Assessing US Pharmaceutical Policy and Pricing Reform Legislation in Light of European Price and Cost Control Strategies. J Health Polit Policy Law. 2022; 47(6):755-778. DOI: 10.1215/03616878-10041163. View

17.

Hunter A, Facey K, Thomas V, Haerry D, Warner K, Klingmann I . EUPATI Guidance for Patient Involvement in Medicines Research and Development: Health Technology Assessment. Front Med (Lausanne). 2018; 5:231. PMC: 6136274. DOI: 10.3389/fmed.2018.00231. View

18.

Rosenberg S . Progress in human tumour immunology and immunotherapy. Nature. 2001; 411(6835):380-4. DOI: 10.1038/35077246. View

19.

Yoo S, Kim D, Lee S, Kang W, Kim S, Lee J . Improving Patient Access to New Drugs in South Korea: Evaluation of the National Drug Formulary System. Int J Environ Res Public Health. 2019; 16(2). PMC: 6352121. DOI: 10.3390/ijerph16020288. View

20.

Garon E, Hellmann M, Rizvi N, Carcereny E, Leighl N, Ahn M . Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol. 2019; 37(28):2518-2527. PMC: 6768611. DOI: 10.1200/JCO.19.00934. View